Sensus Healthcare, Inc. (NASDAQ:SRTS) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Sensus Healthcare, Inc. (NASDAQ:SRTS) have been given an average recommendation of “Moderate Buy” by the six research firms that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $5.8333.

A number of research analysts recently commented on the company. Alliance Global Partners reiterated a “buy” rating on shares of Sensus Healthcare in a report on Monday, August 17th. Lake Street Capital decreased their price target on Sensus Healthcare from $4.50 to $4.00 and set a “buy” rating on the stock in a research note on Friday, August 14th. Finally, Weiss Ratings downgraded Sensus Healthcare from a “sell (d)” rating to a “sell (d-)” rating in a research report on Tuesday, August 18th.

Insiders Place Their Bets

In related news, Director Eric Sachetta purchased 37,537 shares of the company’s stock in a transaction on Friday, August 28th. The stock was acquired at an average cost of $3.44 per share, for a total transaction of $129,127.28. Following the completion of the transaction, the director directly owned 267,480 shares in the company, valued at approximately $920,131.20. The trade was a 16.32% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Insiders have bought a total of 120,171 shares of company stock worth $405,230 over the last ninety days. Company insiders own 10.20% of the company’s stock.

Hedge Funds Weigh In On Sensus Healthcare

Several large investors have recently made changes to their positions in SRTS. North Star Investment Management Corp. purchased a new position in shares of Sensus Healthcare during the 1st quarter worth approximately $500,000. Bank of New York Mellon Corp purchased a new stake in Sensus Healthcare in the second quarter valued at approximately $303,000. BlackRock Inc. acquired a new position in Sensus Healthcare during the second quarter worth $252,000. Finally, EP Wealth Advisors LLC acquired a new position in Sensus Healthcare during the second quarter worth $49,000. 25.30% of the stock is currently owned by institutional investors and hedge funds.

Sensus Healthcare Stock Performance

NASDAQ SRTS opened at $3.12 on Friday. The stock’s fifty day moving average is $3.11 and its two-hundred day moving average is $3.43. The firm has a market capitalization of $51.36 million, a P/E ratio of -3.32 and a beta of 1.13. Sensus Healthcare has a fifty-two week low of $2.66 and a fifty-two week high of $5.49.

Sensus Healthcare (NASDAQ:SRTS) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.41). Sensus Healthcare had a negative return on equity of 21.57% and a negative net margin of 88.45%.The company had revenue of $2.29 million for the quarter, compared to analysts’ expectations of $4.60 million.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc is a medical device company focused on noninvasive treatments for dermatologic and oncologic conditions. The company develops and commercializes superficial radiation therapy systems designed to deliver low-energy X-rays to targeted areas of the skin while limiting exposure to surrounding tissue.

Its principal products include the SRT-100 and SRT-100 Vision systems, which are used primarily to treat non-melanoma skin cancers such as basal cell and squamous cell carcinomas, as well as certain keloid scars.